[The leuko-stimulating and protective action of human recombinant interleukin-1 beta (betaleukin) in the chemotherapy of malignant tumors]

Vopr Onkol. 2000;46(3):278-84.
[Article in Russian]

Abstract

The investigation was concerned with the leuko-stimulating effect of interleukin-1 beta injected subcutaneously (4.6 +/- 0.3 ng/kg body), daily, for 10 days, to treat toxic leukopenia and neutropenia stage III in cancer patients. Complete recovery of leukocyte levels and granulocytic count (during an average of 9 +/- 1 days) was registered within a period similar to that of intravenous dropwise injection of a single dose of 10-20 ng/kg body. Distinct protective effect on leukopoiesis was achieved following subcutaneous injection of II-1 beta (4.3 +/- 0.2 ng/kg body) in patients with basic leukopenia stage II and neutropenia stage I carried out in conjunction with combination chemotherapy. Due to side effect cytostatic drug administration could be continued.

Publication types

  • Clinical Trial
  • Comparative Study
  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Female
  • Granulocytes / drug effects
  • Humans
  • Infusions, Intravenous
  • Injections, Subcutaneous
  • Interleukin-1 / administration & dosage*
  • Leukopoiesis / drug effects*
  • Male
  • Middle Aged
  • Neoplasms / blood
  • Neoplasms / complications
  • Neoplasms / drug therapy*
  • Recombinant Proteins / administration & dosage
  • Stimulation, Chemical

Substances

  • Antineoplastic Agents
  • Interleukin-1
  • Recombinant Proteins